Amgen takes lead with new cholesterol control drug, augmented reality medicine

SAFETY BRIEFING: Devon Zayas, left, and Scott Lyons, senior associates in the process-development division at Amgen’s laboratory in West Greenwich, conduct a pre-job safety briefing for hand-valve manipulations on the 100-liter stainless-steel bioreactor. / PBN PHOTO/RUPERT WHITELEY
SAFETY BRIEFING: Devon Zayas, left, and Scott Lyons, senior associates in the process-development division at Amgen’s laboratory in West Greenwich, conduct a pre-job safety briefing for hand-valve manipulations on the 100-liter stainless-steel bioreactor. / PBN PHOTO/RUPERT WHITELEY
Amgen Rhode Island | Overall Excellence | More than 500 Employees “We have a mantra, ‘Serving every patient, every time.’ It’s the rally cry of our ­organization,” said Tia Bush, vice president of Amgen Inc.’s Rhode Island and ­Woburn, Mass., operations. “It’s there when we evaluate our work, get our products to patients and make…

You must be a subscriber to read this content. To keep reading and receive unlimited access subscribe today for only $1.
Subscribe Now Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

No posts to display